ClinicalTrials.gg
RecruitingNCT06928506RECLAIM-HiOxSRUpdated Oct 22, 2026

Effect of Hi-OxSR for the Treatment of Post COVID Condition

An interventional study of Hi-OxSR device and Hi-Ox device in Long COVID, Post COVID-19 Condition and Post Acute Sequelae of COVID-19, sponsored by University Health Network, Toronto. Recruiting at 3 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by University Health Network, Toronto · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.
Updated Oct 22, 2026Site recruiting status changedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Post-Acute COVID-19 Syndrome with a site in Canada — 14 open to participants now, 17 under way, 3 of them phase 3. Post-Acute COVID-19 Syndrome · Canada.

Planned enrollment
10th of 33
120 · median 82
Started
2025
with 6 others
No phase
23 of 40
6 open now
Primary completion
2028-02
later than 12 of 16 live
Registered
33rd of 40
by date
Lead sponsor
4 of 40
University Health Network, Toronto

Among the 40 studies in Post-Acute COVID-19 Syndrome with a site in Canada, this one is the 10th largest by planned enrollment of the 33 interventional ones that give a count, is one of 7 that started in 2025, is one of 23 with no phase, reaches primary completion later than 12 of the 16 other live ones, and was the 33rd registered.

Post-Acute COVID-19 Syndrome

606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

Browse Post-Acute COVID-19 Syndrome studies →

Open to participants now

14 of the 40 studies in Post-Acute COVID-19 Syndrome with a site in Canada are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Post-Acute COVID-19 Syndrome with a site in Canada, or all of them as a file.
02

Study summary

The RECLAIM study platform will be used to explore whether the use of the Hi-OxSR device improves the symptoms of post covid cognitive dysfunction. Carbon dioxide (CO2) has been proposed as a potential treatment for persistent immune activation as there is evidence that CO2 has antioxidant, anti-inflammatory, and anti-cytokine effects. We conducted a pilot study assessing the open label use of re-breathing CO2 (using Hi-OxSR) twice a day for 14 days, for the treatment of post-COVID cognitive dysfunction. Significant improvements were found in multiple cognitive assessments using TestMyBrain cognitive tests and brain fog (MSNQ) and fatigue scores. This phase 2 clinical trial seeks to build on current findings to determine the optimal effective dose of treatment (i.e. length of use, oxygen concentration, without or without CO2 rebreathing) and the safety of using Hi-OxSR in this patient population.

Read the detailed description

This is a Sub-Protocol to the Core Clinical Study Protocol titled: REcovering from COVID-19 Lingering symptoms Adaptive Integrative Medicine (RECLAIM)

03

Conditions studied

  • Long COVID
  • Post COVID-19 Condition
  • Post Acute Sequelae of COVID-19
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years;
  2. Positive COVID-19 test by nasopharyngeal swab RT-PCR (reverse transcription polymerase chain reaction) test, antibody or antigen tests at least 3 months prior to randomization; OR Presumed COVID-19 assessed by the site investigator (no positive COVID-19 test) with acute illness after October 15, 2019.
  3. Patients should be treated with standard of care therapies (as discussed in the study manual) for at least 4 weeks prior to entry into trial.
  4. Lingering COVID-19 symptoms beyond 3 months from onset of acute COVID and symptoms have lasted at least 2 months. The onset of COVID is considered the earliest of two dates: the date of positive test or the date of first symptoms;
  5. Lingering symptoms from COVID-19 present at the time of randomization. "Lingering symptoms of Long COVID" must include self-reported cognitive dysfunction symptoms.
  6. Female patients of (as assessed by the overseeing Investigator) who are sexually active must agree to practice true abstinence or use effective methods of while on study treatment. Effective methods of contraception must be discussed and approved by the overseeing Investigator.
  7. Must be able to provide and both willing and able to comply with study requirements.
  8. Oxygen saturation on room air ≥92% at screening measured by pulse oximeter.

Exclusion criteria

Exclusion Criteria:

  1. Patients who had mechanical ventilation or extracorporeal membrane oxygen (ECMO) for COVID-19;
  2. Current end-organ failure, organ transplantation, or current hospitalization in acute care hospital;
  3. to all of the study interventions;
  4. Co-enrolment in another interventional trial (co-enrolment in an observational study is permitted);
  5. Currently pregnant or breastfeeding.
  6. Known physician diagnosis of cognitive dysfunction prior to COVID infection
  7. Use of an drug/device or other interventions within 30 days of screening
  8. Use of home oxygen (O2) at baseline
  9. History of pulmonary hypertension
  10. Interstitial pulmonary fibrosis
  11. Moderate to severe (COPD)
  12. History of narcolepsy
  13. Presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the participant or the quality of the data.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Group 1

    Use of Hi-OxSR for 30 minutes twice a day at low oxygen flow (0.5-3 liters per minute) for 2 weeks.

    Device: Hi-OxSR device

  • Experimental
    Group 2

    Use of Hi-OxSR for 30 minutes twice a day at low oxygen flow (0.5-3 liters per minute) for 4 weeks.

    Device: Hi-OxSR device

  • Active comparator
    Group 3

    Use of Hi-Ox for 30 minutes twice a day at high oxygen flow (5 liters per minute) for 2 weeks.

    Device: Hi-Ox device

Interventions

  • DeviceHi-OxSR device

    The Hi-OxSR device consists of the Hi-Ox mask connected to a portable oxygen concentrator, with added tubing serving as a reservoir for rebreathed exhaled breath.

  • DeviceHi-Ox device

    The Hi-Ox mask is connected to a portable oxygen concentrator.

06

What researchers measure

Primary outcomes

  1. Simple reaction time (SRT) task from the TestMyBrain (TMB) Digital Neuropsychology Toolkit On-line survey tool

    TestMyBrain was developed as a tool to collect large, population-based samples for understanding the relationship between cognition, emotion, social functioning, and health. This test will take about 5 minutes to complete and will assess reaction time.

    Time frame: Baseline/Start of intervention to two months

  2. Verbal paired associates (VPA) task from the TestMyBrain (TMB) Digital Neuropsychology Toolkit On-line survey tool

    TestMyBrain was developed as a tool to collect large, population-based samples for understanding the relationship between cognition, emotion, social functioning, and health. This test will take about 5 minutes to complete and will assess memory.

    Time frame: Baseline/Start of intervention to two months

Secondary outcomes

  1. All cognitive performance tasks (measured by the TESTMYBRAIN.org (TMB) neuropsychology toolkit

    TestMyBrain was developed as a tool to collect large, population-based samples for understanding the relationship between cognition, emotion, social functioning, and health. This test battery will take about 20 minutes to complete and will assess: verbal, episodic and working memory, attention, processing speed, basic psychomotor response speed, and cognitive control.

    Time frame: Baseline/start of intervention to 2 weeks, 1, 2 and 6 months

  2. Brain Fog Questionnaire

    (Adapted from MSNQ) This is a self-administered 15-item questionnaire that assesses neurocognitive function. It takes approximately less than 5 minutes to complete

    Time frame: Baseline/start of intervention to 2 weeks, 1, 2 and 6 months

  3. Brief Fatigue Inventory

    The self-administered Brief Fatigue Inventory is composed of 9 items evaluated on a 10-point scale, assessing severity of fatigue and impact of fatigue on daily life. It takes approximately 2-3 minutes to complete.

    Time frame: Baseline/start of intervention to 2 weeks, 1, 2 and 6 months

  4. Short Form (SF)-36

    Mental health related quality of life, measured by the Mental Composite Score (MCS), and physical health-related quality of life, measured by the Physical Component Score (PCS) of the SF-36 (v.1)

    Time frame: Baseline/start of intervention to 2 weeks, 1, 2 and 6 months

  5. Safety, adverse events and serious adverse events

    Safety of the Hi-OxSR device will be reported through Adverse Events (AEs) and Serious Adverse Events (SAEs) throughout the study period.

    Time frame: Baseline/start of intervention to 6 months

  6. Symptom Checklist

    Symptom Checklist (adapted from the De Paul Symptom Questionnaire (DSQ2), the World Health Organization Global COVID-19 Clinical Platform's Post COVID-19 case report form (CRF) and the Symptom Burden Questionnaire for Long COVID): to track symptom trajectory.

    Time frame: Baseline/start of intervention to 2 and 6 months

  7. The DePaul Symptom Post-Exertional Malaise Short Form DSQ-PEM

    The self-administered DSQ-PEM is comprised of two sections assessing post-exertional malaise (PEM): (i) frequency and severity of PEM (5 questions), (ii) consequences, symptoms and recovery (5 questions).

    Time frame: Baseline/start of intervention to 2 weeks, 1, 2 and 6 months

  8. Dyspnea

    Assessed using the Borg Dyspnea scale. This short assessment tool assesses perceived shortness of breath on exertion using a 10 point scale as assessed by the patient.

    Time frame: Baseline/start of intervention to 2 and 6 months

  9. Mental Health - General Anxiety Assessment Form (GAD-7)

    The GAD-7 is a valid and efficient tool for screening for generalized anxiety disorder and assessing its severity in clinical practice and research. It is an easy-to-use, self-administered patient questionnaire that can be completed in minutes.

    Time frame: Baseline/start of intervention to 2 and 6 months

  10. Mental Health - Patient Health Questionnaire (PHQ-9)

    The PHQ-9 is a validated, multipurpose instrument for screening, diagnosing, monitoring and measuring the severity of depression. It incorporates Diagnostic and Statistical Manual IV (DSM-IV) depression diagnostic criteria with other leading major depressive symptoms into a brief self-report tool. The PHQ-9 is brief and useful in clinical practice.

    Time frame: Baseline/start of intervention to 2 and 6 months

  11. Mental Health -Post-traumatic Stress Disorder Checklist (PCL-5)

    The PCL-5 is a validated, reliable, 20-item self-report measure that assesses the 20 Diagnostic and Statistical Manual 5 (DSM-5) symptoms of Post-Traumatic Stress Disorder (PTSD). It takes approximately 5-10 minutes to complete.

    Time frame: Baseline/start of intervention to 2 and 6 months

  12. Reintegration to Normal Living Index (RNLI)

    This short self-administered assessment tool will determine the degree to which participants reintegrate into normal social activities such as recreation, mobility in the community and interaction in family and other relationships. This tool has been validated in community living adults with mobility limitations.

    Time frame: Baseline/start of intervention to 2 and 6 months

  13. Blood samples

    Blood samples will be used in correlative studies using advanced multi-omic and machine learning methods to better understand our results so as to identify phenotypes that will benefit from specific therapies

    Time frame: Baseline/start of intervention and 2 months

  14. Fatigue Scale (adapted from the De Paul Symptom Questionnaire (DSQ2)

    The Fatigue Scale was adapted from the De Paul Symptom Questionnaire (DSQ2)'s 38 questions assessing medical history of Myalgia encephalomyelitis/chronic fatigue syndrome (ME/CFS), comorbidities, medications, impact on quality of life and daily activities, etc.

    Time frame: Baseline/start of intervention to 2 weeks, 1, 2 and 6 months

07

Study locations

3 of 3 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Feb 2028, 30 months after the start.

Of 232 non-industry interventional studies with no phase under Post-Acute COVID-19 Syndrome, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's planned 30 months is above that.

Counting every sponsor, half of 243 studies reached it within 16 months; a quarter within 7 and three quarters within 27.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: primary completion Dec 2027 → Feb 2028 and completion Dec 2028 → Apr 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2025
First posted
Apr 15, 2025
StartActual
Aug 1, 2025
Primary completionEst.
Feb 2028was Dec 2027
CompletionEst.
Apr 2029was Dec 2028
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • Kaye Edmonton Clinic · Edmonton, CanadaNot yet recruiting→Recruiting
  • Centre Hospitalier Universitaire de Sherbrooke · Sherbrooke, CanadaNot yet recruiting→Recruiting
Oct 22, 2026
Primary completion
Dec 2027→Feb 2028
Oct 22, 2026
Study completion
Dec 2028→Apr 2029
Oct 22, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Kaye Edmonton Clinic · Edmonton, CanadaContact p•••@ualberta.ca→P•••@albertahealthservices.ca
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Kaye Edmonton Clinic · Edmonton, CanadaNot yet recruiting→Recruiting
    • Centre Hospitalier Universitaire de Sherbrooke · Sherbrooke, CanadaNot yet recruiting→Recruiting
    Primary completion Dec 2027→Feb 2028
    Study completion Dec 2028→Apr 2029
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Kaye Edmonton Clinic · Edmonton, CanadaContact p•••@ualberta.ca→P•••@albertahealthservices.ca
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06928506
Responsible party
Sponsor
First posted
Apr 15, 2025
Start date
Aug 1, 2025
Primary completion
Feb 2028 (estimated)
Completion
Apr 2029 (estimated)
Last update
Oct 22, 2026

Study contacts

suzanne Cohen
Contact
reclaim@uhn.ca
1-866-673-2524
Angela M Cheung, MD, PhD
principal investigator · University Health Network, Toronto

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion